BIIB News and Press, Biogen Inc. From 12/07/23

2023-12-07 15:13:39 ET More on Biogen Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Biogen's Uncertain Strategic Pivots Amidst MS Market Challenges Ionis says Angelman syndrome drug well ...

2023-12-06 13:16:08 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-12-05 03:58:10 ET Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anav...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-11-29 18:23:20 ET More on Lexeo Therapeutics, Inc. Stocks To Watch: Spotlight On OPEC Meeting, Amazon AWS Event, Tesla's Cybertruck Reveal, And Box Office Drama Lexeo Therapeutics Proposes Terms For $126 Million IPO Lexeo Therapeutics Starts $100 Million U.S. IP...

2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...

2023-11-28 12:12:06 ET Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference November 28, 2023 9:10 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Umer Raffat - Evercore ISI Presentation Um...

2023-11-19 12:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Perfectly Priced Healthcare Giant Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event (Transcript) Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise ...

2023-11-13 23:41:22 ET Summary Anavex's Alzheimer's drug Blarcamesine demonstrates strong statistical significance in improving cognition among dementia patients as measured by one co-primary endpoint and one secondary endpoint. For the other co-primary endpoint, it seems the drug...

2023-11-13 05:41:04 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) on Saturday shared positive clinical findings from an ongoing trial of its investigational antisense medicine, ION582, in Angelman syndrome (AS). ION582, which is being developed under a strategic collaboration wi...